TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03904550
Drug: Rocuronium + Sugammadex
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
Study: NCT01007409
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
Study: NCT01007409
Drug: Fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
Study: NCT02054754
Drug: Dexanabinol Dose Level 1
Normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of dexanabinol
Study: NCT02054754
Drug: Dexanabinol Dose Level 2
Normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of dexanabinol
Study: NCT02054754
Drug: Dexanabinol Dose Level 3
Normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of dexanabinol
Study: NCT02054754
Drug: Dexanabinol Dose Level 4
Normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of dexanabinol
Study: NCT02054754
Drug: Dexanabinol Dose Level 5
Normalized name: peanut allergenic extract
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of dexanabinol
Study: NCT02938520
Drug: Cabotegravir - Injectable Suspension (CAB LA)
Normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
Study: NCT02938520
Drug: Rilpivirine - Injectable Suspension (RPV LA)
Normalized name: rilpivirine Injection
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study: NCT00179673
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
Study: NCT01269476
Drug: SNX-001
Normalized name: SNX-2112
DrugBank: SNX-2112 (DB17055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6, 7.2, or 10.8 mg single dose or t.i.w.
Study: NCT01921335
Drug: ARRY-380 Twice Daily Dosage
Normalized name: clindamycin
DrugBank: Sage (DB10982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
Study: NCT01921335
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 mg/kg IV every 3 weeks
Study: NCT03584217
Drug: Aminohippurate Sodium Inj 20%
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study: NCT03584217
Drug: Iohexol Inj 300 MG/ML
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study: NCT02292550
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK 4/6 inhibitor
Study: NCT02292550
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ALK inhibitor
Study: NCT02214706
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
Study: NCT01287715
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
Study: NCT01287715
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
Study: NCT02243137
Drug: prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration: one loading dose (60mg)
Study: NCT02990078
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
Study: NCT03267654
Drug: gefitinib combined with chemotherapy
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit.
Study: NCT03267654
Drug: gefitinib combined with apatinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death.
Study: NCT03267654
Drug: gefitinib single agent
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
Study: NCT02241174
Drug: Sodium Hypochlorite
Normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
Study: NCT03393741
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study: NCT03393741
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study: NCT03393741
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
Study: NCT00981227
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scored tablets
Study: NCT00997126
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
Study: NCT01609582
Drug: TAK-875
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 tablets
Study: NCT00277160
Drug: Neulasta (pegfilgrastim)
Normalized name: pegfilgrastim Injection [Neulasta]
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
Study: NCT04491695
Drug: Tirofiban Hydrochloride
Normalized name: Tirofiban Hydrochloride
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
Study: NCT04491695
Drug: Oral antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
Study: NCT00118365
Drug: eflornithine
Normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00964873
Drug: STA-9090 (ganetespib)
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy agent
Study: NCT00051831
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered as one 200-mg capsule orally daily
Study: NCT00051831
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
Study: NCT00051831
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered as one 100-mg capsule orally twice daily
Study: NCT00051831
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered as five hard gel capsules orally twice daily
Study: NCT01852578
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
Study: NCT00051831
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered as one 300-mg tablet orally daily
Study: NCT03067740
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
Study: NCT03067740
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
Study: NCT01808248
Drug: PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT01808248
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00162201
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
Study: NCT01059799
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study: NCT01059799
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
Study: NCT02667574
Drug: ERIVEDGE
Normalized name: Erivedge
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00821977
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00547092
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
Study: NCT00547092
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
Study: NCT00003596
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003596
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00024349
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01489592
Drug: curcuma longa
Normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of 6 grams of curcumin
Study: NCT00997126
Drug: Alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
Study: NCT01719523
Drug: EPI-743
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02245490
Drug: Tamsulosin HCl controlled release capsules
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00941473
Drug: Triamcinilone (kenalog)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural steroid injection of 80mg of Triamcinilone.
Study: NCT01432028
Drug: Estradiol and Progesterone
Normalized name: ESTRADIOL/PROGESTERONE
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
Study: NCT02438540
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin tablet 500 mg
Study: NCT04479748
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment of pain and inflammation following ophthalmic surgery
Study: NCT03509285
Drug: Alprazolam Placebo
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg lactose tablets
Study: NCT03509285
Drug: Cenobamate placebo
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugar pill manufactured to mimic cenobamate 100 mg tablet
Study: NCT03509285
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg and 1.0 mg alprazolam tablets
Study: NCT03509285
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg tablet
Study: NCT00432627
Drug: Deferasirox
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one dose of 20 mg/kg/day
Study: NCT05340192
Drug: Octreotide 1 MG/ML
Normalized name: octreotide 1 MG/ML
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mcg (1 ml) of Octreotide
Study: NCT00645151
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
Study: NCT01699828
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The buspirone will be given once as a tablet and encapsulated for blinding.
Study: NCT02568007
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01705652
Drug: Nexrutine
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
Study: NCT00447161
Drug: Bacillus Clausii Multi ATB Resist
Normalized name: Bacillus clausii
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
Study: NCT03179748
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
Study: NCT01114581
Drug: Mucinex
Normalized name: Mucinex
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
Study: NCT04290494
Drug: IV rtPA (intravenous recombinant plasminogen activator)
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT02700815
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04691440
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
Study: NCT02569307
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
Study: NCT01000688
Drug: vildagliptin + acarbose
Normalized name: vildagliptin
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 week treatment
Study: NCT01000688
Drug: acarbose + vildagliptin
Normalized name: vildagliptin
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 week treatment
Study: NCT00004490
Drug: sodium dichloroacetate
Normalized name: sodium dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02299687
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00890942
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naloxone 0.4mg.(1 ml) intramuscular
Study: NCT03876028
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral (tablets or capsules)
Study: NCT01754376
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous therapy given every 8 hours for up to 14 doses per week.
Study: NCT01754376
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets given twice daily.
Study: NCT01964872
Drug: JNJ-38877618: Part 1a
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study: NCT01964872
Drug: JNJ-38877618: Part 1b
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study: NCT01964872
Drug: JNJ-38877618: Part 1c (optional)
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study: NCT01964872
Drug: JNJ-38877618: Part 2
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study: NCT01964872
Drug: JNJ-38877618: Part 3
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
Study: NCT01964872
Drug: JNJ-38877618: Part 4 (optional)
DrugBank: JNJ-38877618 (DB16883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.